LIQUI SRS

Serial Number 98256227
688

Registration Progress

Application Filed
Nov 6, 2023
Under Examination
Apr 8, 2025
Approved for Publication
Feb 11, 2025
Published for Opposition
Feb 11, 2025
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Oct 08, 2025 66 days

Trademark Image

LIQUI SRS

Basic Information

Serial Number
98256227
Filing Date
November 6, 2023
Published for Opposition
February 11, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
688
Status Date
Apr 8, 2025
Application
Pending
Classes
005 042

Rights Holder

EMOVIAR PharmaCon GmbH

16
Address
Merianstraße 53
D-79664 Wehr 79664
DE

Ownership History

EMOVIAR PharmaCon GmbH

Original Applicant
16
D-79664 Wehr DE

EMOVIAR PharmaCon GmbH

Owner at Publication
16
D-79664 Wehr DE

Legal Representation

Attorney
Elizabeth M. O'Donoghue

USPTO Deadlines

Next Deadline
66 days remaining
NOA E-Mailed - SOU Required
Due Date
October 08, 2025
Extension Available
Until April 08, 2026

Application History

27 events
Date Code Type Description Documents
Jul 7, 2025 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Jul 7, 2025 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jul 7, 2025 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Jul 7, 2025 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jul 7, 2025 EWAF I TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS Loading...
Jul 7, 2025 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Jul 7, 2025 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Apr 8, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Feb 11, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Feb 11, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 5, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 22, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 6, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Dec 6, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 6, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Sep 18, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Sep 18, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Sep 18, 2024 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jul 31, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jul 31, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 31, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jun 26, 2024 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jun 26, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jun 26, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jun 14, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 30, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Nov 9, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical drugs for the treatment and prevention of chronic and non-chronic diseases, namely, pain diseases, cardiovascular diseases, cancer diseases, infectious diseases, neural diseases, respiratory diseases, obesity diseases, and kidney diseases; Drug delivery agents in particular sustained release agents in the form of capsules and tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drugs for medical for purposes in particular sustained release drug formulations for the treatment and prevention of chronic and non-chronic diseases, namely, pain diseases, cardiovascular diseases, cancer diseases, infectious diseases, neural diseases, respiratory diseases, obesity diseases, and kidney diseases
Class 042
Drug discovery services; biological research; clinical research in the medical, pharmaceutical, and biotechnology fields; medical research; research on the subject of pharmaceuticals; research and development in the pharmaceutical and biotechnology fields; research and development in the pharmaceutical and biotechnology fields for the pharmaceutical industry; pharmaceutical products development; pharmaceutical formulation in the nature of pharmaceutical products development; biomedical research services; medical and scientific research in the field of pharmacogenetics; research and development of vaccines and medicines; pharmaceutical drug development services; development of pharmaceutical preparations in particular sustained release formulations and medicines; pharmaceutical research services.

Classification

International Classes
005 042